Longboard Pharmaceuticals (Nasdaq:LBPH) - 주가, 뉴스 및 분석

LBPH 주식 개요

임상 단계의 바이오 제약 회사인 롱보드 파마슈티컬스는 신경 질환을 위한 새롭고 혁신적인 의약품을 개발하는 데 주력하고 있습니다. 자세한 내용

LBPH 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 크게 희석되었습니다.

최근 3개월간 주가 변동폭 심해

수익은 향후 3년간 연평균 7.6% 씩 감소할 것으로 예상됩니다.

+ 1 더 많은 위험

Longboard Pharmaceuticals, Inc. 경쟁사

Ligand Pharmaceuticals

NasdaqGM:LGND

US$2.3b

Wave Life Sciences

NasdaqGM:WVE

US$2.2b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Belite Bio

NasdaqCM:BLTE

US$2.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Longboard Pharmaceuticals
과거 주가
현재 주가	US$59.95
52주 최고치	US$59.95
52주 최저치	US$3.60
베타	1.09
11개월 변경	0.59%
3개월 변경 사항	70.80%
1년 변경 사항	1,457.14%
33년 변화	971.49%
5년 변화	n/a
IPO 이후 변화	260.06%

최근 뉴스 및 업데이트

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

Recent updates

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Jul 12

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12

Longboard Pharmaceuticals EPS beats by $0.29

May 10

주주 수익률

	LBPH	US Pharmaceuticals	US 마켓
7D	0.2%	2.8%	2.2%
1Y	1,457.1%	11.8%	32.6%

수익률 대 산업: LBPH 지난 1년 동안 11.8 %를 반환한 US Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: LBPH 지난 1년 동안 32.6 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is LBPH's price volatile compared to industry and market?
LBPH volatility
LBPH Average Weekly Movement	16.9%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

안정적인 주가: LBPH 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: LBPH 의 주간 변동성은 지난 1년 동안 46% 에서 17% 로 감소했지만 여전히 US 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
2020	50	Kevin Lind	www.longboardpharma.com

임상 단계의 바이오 제약 회사인 롱보드 파마슈티컬스는 신경 질환을 위한 새롭고 혁신적인 의약품을 개발하는 데 주력하고 있습니다. 이 회사는 발달 및 간질성 뇌병증과 관련된 발작 치료를 위한 임상 1b/2a상 시험을 완료한 벡사세린(LP352)을 개발하고 있습니다. 또한 신경계 질환 치료를 위한 S1P 수용체 조절제인 LP659를 개발하고 있습니다.

Longboard Pharmaceuticals, Inc. 기본 사항 요약

Longboard Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
LBPH 기본 통계
시가총액	US$2.34b
수익(TTM)	-US$76.34m
수익(TTM)	n/a

0.0x

P/S 비율

-30.7x

P/E 비율

LBPH 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
LBPH 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$76.34m
수익	-US$76.34m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.96
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

LBPH 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

LBPH 주식 개요

위험 분석

Longboard Pharmaceuticals, Inc. 경쟁사

NasdaqGM:LGND

US$2.3b

NasdaqGM:WVE

US$2.2b

NasdaqGS:AMPH

US$2.1b

NasdaqCM:BLTE

US$2.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Recent updates

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) dropped from Russell Small Cap Comp Value Index

Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin (Lp352)

Price target decreased by 7.2% to US$41.75

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

New major risk - Revenue and earnings growth

Longboard Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $210 million.

Price target increased by 43% to US$28.67

Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (Dees)

Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers

New minor risk - Market cap size

New minor risk - Share price stability

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

New major risk - Financial position

Price target decreased by 14% to US$17.00

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

High number of new and inexperienced directors

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Price target decreased to US$19.74

Price target decreased to US$22.80

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 24, 2022

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals Provides Corporate Update

Longboard Pharmaceuticals EPS beats by $0.29

주주 수익률

가격 변동성

회사 소개

Longboard Pharmaceuticals, Inc. 기본 사항 요약

0.0x

-30.7x

수익 및 수익